LY3295668
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neoplasms
Conditions
Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms, Head and Neck Neoplasms, Breast Neoplasms, Solid Tumor, Adult, Small Cell Lung Carcinoma
Trial Timeline
May 29, 2017 → Apr 20, 2020
NCT ID
NCT03092934About LY3295668
LY3295668 is a phase 1/2 stage product being developed by Eli Lilly for Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT03092934. Target conditions include Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03092934 | Phase 1/2 | Completed |
Competing Products
20 competing products in Neoplasms